JP2012509886A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509886A5
JP2012509886A5 JP2011537606A JP2011537606A JP2012509886A5 JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5 JP 2011537606 A JP2011537606 A JP 2011537606A JP 2011537606 A JP2011537606 A JP 2011537606A JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5
Authority
JP
Japan
Prior art keywords
tcl1
activator protein
promotes
pharmaceutical composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065072 external-priority patent/WO2010059779A1/en
Publication of JP2012509886A publication Critical patent/JP2012509886A/ja
Publication of JP2012509886A5 publication Critical patent/JP2012509886A5/ja
Pending legal-status Critical Current

Links

JP2011537606A 2008-11-21 2009-11-19 転写制御因子としてのTcl1 Pending JP2012509886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (2)

Publication Number Publication Date
JP2012509886A JP2012509886A (ja) 2012-04-26
JP2012509886A5 true JP2012509886A5 (enExample) 2012-06-07

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537606A Pending JP2012509886A (ja) 2008-11-21 2009-11-19 転写制御因子としてのTcl1

Country Status (7)

Country Link
US (1) US20110311555A1 (enExample)
EP (1) EP2352524A1 (enExample)
JP (1) JP2012509886A (enExample)
CN (1) CN102271706A (enExample)
AU (1) AU2009316584A1 (enExample)
CA (1) CA2744326A1 (enExample)
WO (1) WO2010059779A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
ES2524018T3 (es) 2006-01-05 2014-12-03 The Ohio State University Research Foundation Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロrna発現サイン
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
CA2690144A1 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CN101836112A (zh) 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
ES2555307T3 (es) * 2002-03-08 2015-12-30 Eisai R&D Management Co., Ltd. Compuestos macrocíclicos útiles como agentes farmacéuticos

Similar Documents

Publication Publication Date Title
JP2012509886A5 (enExample)
EA200870265A1 (ru) Функционально активные антитела
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
UA113712C2 (xx) Антитіло до fap і способи його застосування
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
IL186671A (en) Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs
JP2007051159A5 (enExample)
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2012012927A (es) Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
JP2006506333A5 (enExample)
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
NZ606880A (en) Antibodies to matrix metalloproteinase 9
EA201700111A1 (ru) Полипептидные конструкции и их применение
EA202192294A1 (ru) Антитела к trem2 и способы их применения
GEP20135930B (en) ANTI-cMET ANTIBODY
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
HUE060029T2 (hu) Emberi antitestek, amelyek kötnek limfocita aktivációs gént-3 (LAG-3) és azok felhasználásai
JP2015500002A5 (enExample)
EA201400390A1 (ru) Антитела к tl1a и их применение
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
JP2007520566A5 (enExample)
JP2008535821A5 (enExample)